Stock listing

Frankfurt:8EV TheraCryf PLC Aktie

German listing (Frankfurt) of TheraCryf PLC · home listing LSE:TCF

Follow TheraCryf PLC into a list and get an email when it puts out news.

Share price · FWB:8EV

€0.0005 EUR 0.0000 (0.0%)

Close on Nov 20, 2026

Past year 0.0% · daily closes, Nov 21, 2025 – Nov 4, 2026, adjusted for splits
Day range
€0.0005 – €0.0005 EURNov 20, 2026
Market cap
€5.29M EURAt the close on Nov 20, 2026 · price × 10.58B shares outstanding
52-week range
€0.0005 – €0.0010 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€0 EURMedian day 0 shares · 34 days with no trades · last 3 months, Aug 21, 2026 – Nov 4, 2026
TheraCryf PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:TCF · Home0.165p GBX (pence)0.000 (0.0%)41,2370.165p0.165p0.161p0.165pClose on Nov 20, 2026
Frankfurt:8EV€0.0005 EUR0.0000 (0.0%)—€0.0005€0.0005€0.0005€0.0005Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 21, 2026 – Nov 4, 2026 · FWB:8EV · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00102,400
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
€0.00100.00000.0%€0.0010€0.0010€0.00100
Ticker
Frankfurt:8EV
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All TheraCryf PLC news

TheraCryf PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 236 in all · newest Nov 18, 2026 · oldest 2007
Calls
12 calls with a replay · 12 with a transcript · latest Oct 20, 2026
Decks
15 decks · latest Sep 7, 2026

Where TheraCryf PLC is listed

ListingExchangeCountryCurrency
LSE:TCF · Home listingLSEUnited KingdomGBX
Frankfurt:8EV · This pageFrankfurtGermanyEUR

Valuation

Price/book 1.3× against a median of 1.2×: 5th lowest of 8 Biotechnology companies shown. Statements: Year to Mar 31, 2026 · price Nov 20, 2026

Enterprise value
£2.01M GBP
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
TheraCryf PLC · LSE:TCFUS$4.64MUS$2.63Mn/an/an/a1.3×n/a0.0×n/a
Oncodesign Precision Medicine S.A. · EURONEXT:ALOPMUS$5.04MUS$8.61M0.8×30.0×0.9×1.2×n/a1.6×n/a
Patrys Limited · ASX:PABUS$4.96MUS$4.47Mn/a8.2×n/a10.2×−363.7%0.0×n/a
Invex Therapeutics Ltd. · ASX:IXCUS$4.86MUS$2.20Mn/an/an/a1.9×n/a0.0×n/a
Can-Fite BioPharma Ltd. · TASE:CANFUS$4.86M−US$2.14Mn/a−5.3×n/a1.0×n/a0.0×n/a
Zenith Capital Corporation · OTC:ZHCLFUS$4.83Mn/an/an/an/an/an/an/a0.06
NFL Biosciences SA · EURONEXT:ALNFLUS$4.71MUS$5.36Mn/an/an/an/an/an/an/a
Pulmatrix, Inc. · NASDAQ:PULMUS$4.64MUS$3.24Mn/an/an/a3.5×n/a0.0×0.33
AIM ImmunoTech Inc. · AMEX:AIMUS$4.57M−US$937,186n/a−10.3×n/a0.7×n/a0.2×0.66
Tissue Repair Ltd · ASX:TRPUS$4.40MUS$1.24Mn/a3.4×n/a0.8×−958.0%0.0×n/a
Processa Pharmaceuticals, Inc. · NASDAQ:PCSAUS$4.37M−US$175.8Mn/an/an/an/an/an/a1.60
Median of the othersUS$4.77MUS$2.20M0.8×3.4×0.9×1.2×−660.9%0.0×0.50

Forecasts

Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
1.21 GBX · Analysts' mean
EPS, year to Mar 2027
-0.001 · 1 analyst

Team and board

Officers

OfficerRole
Alastair SmithChief Executive Officer
Huw JonesChief Executive Officer
Toni HaenninenChief Financial Officer
Helen KuhlmanChief Operating Officer
Andy ThackerNorthstar Communications Investor Relations
Guy McDougallNorthstar Communications Investor Relations
Glen ClackChief Medical Officer

Board

DirectorRole
Alastair SmithChief Executive Officer
Alan BargeNon-Executive Director
Edward WardleNon-executive Director

Events

Results days

QuarterResultsShare move
Q2 2026Dec 3, 2025+10.5%
Q4 2025Jun 2, 2025−3.6%
Q2 2025Nov 28, 2024−2.3%
Q2 2023Dec 5, 2022−7.0%
Q4 2022Jun 8, 20220.0%
Q2 2022Dec 8, 2021−5.6%
Q4 2021Jun 14, 2021−5.9%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (September 2026)Shareholder meeting14 slidesSep 7, 2026
Investor Presentation (November 2025)Investor deck21 slidesNovember 2025
Investor Presentation (February 2025)Investor deck22 slidesFebruary 2025
Investor Presentation (May 2024)Investor deck12 slidesMay 2024
Evgen Pharma — Merger or Acquisition (April 2024)Merger or acquisition12 slidesApril 2024
Evgen Pharma — Merger or Acquisition (March 2024)Merger or acquisition13 slidesMarch 2024
Evgen Pharma — Corporate Update (2023)Corporate update13 slides2023
Evgen Pharma — H1 2022 Earnings PresentationEarnings10 slidesDecember 2022
Evgen Pharma — Investor Presentation (February 2022)Investor deck13 slidesFebruary 2022
Evgen Pharma — Shareholder Meeting (July 2021)Shareholder meeting13 slidesJul 13, 2021
All 15 decks
DeckKindSlidesDate
Evgen Pharma — Shareholder Meeting (July 2020)Shareholder meeting20 slidesJul 16, 2020
Evgen Pharma — Shareholder Meeting (July 2019)Shareholder meeting16 slidesJul 18, 2019
Evgen Pharma — FY2018 Earnings PresentationEarnings41 slidesJune 2018
Evgen Pharma — Investor Presentation (May 2018)Investor deck29 slidesMay 2018
Evgen Pharma — H1 2016 Earnings PresentationEarnings34 slidesDecember 2015

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares (Placing Shares and Subscription Shares)
Announced: about £1.05M · GBX 0.18 a share · Turner Pope +1
Dealers: Turner Pope (lead), Singer Capital Markets (co-lead)
Buyers: Northern Standard Limited (138,888,888 Subscription Shares; 20.8% of Enlarged Share Capital following Admission); Dr Huw Jones (5,555,555 Subscription Shares); Toni Haenninen (via Borealito GmbH) (4,444,444 Subscription Shares); Dr Alastair Smith (13,888,888 Subscription Shares); Dr Nicholas Mallard (2,777,777 Subscription Shares); Dr Glen Clack (1,388,888 Subscription Shares); Dr Helen Kuhlman (3,333,333 shares)
Insiders: Certain PDMRs to subscribe for an aggregate 28,055,552 New Ordinary Shares through the PDMR Subscription
Use of proceeds: Complete clinic-enabling programme for Ox-1 addiction asset, apply for Phase 1 approval in Australia, and extend cash runway to end Q1 2027
Aug 20, 2026US$1.43M
Private placement of new ordinary shares
Update: £4.25M · £0.0025 a share · Turner Pope Investments (TPI) Limited
Dealers: Turner Pope Investments (TPI) Limited (lead)
Buyers: Tracarta Limited (£1,000,000 for 400,000,000 new Ordinary Shares); Dr Alastair Smith (4,000,000 Ordinary Shares); Dr Huw Jones; Toni Hänninen
Insiders: Directors and PDMRs subscribing £28,000 for 11,200,000 new Ordinary Shares; a related party transaction
Use of proceeds: Pre-clinical development of Ox-1 orexin-1 antagonist, SFX-01 tablet manufacturing, patent portfolio, consultants and general corporate purposes
Mar 7, 2025US$5.35M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue00396.0K442.0K0194.0K
Cost of revenue16.0K2.11M11.0K13.0K16.0K3.39M21.0K21.0K21.0K17.0K
Gross profit-16.0K-2.11M385.0K429.0K-16.0K-3.19M-21.0K-21.0K-21.0K-17.0K
Research and development2.76M398.0K2.77M4.72M2.60M2.73M1.70M1.69M1.67M2.10M
Selling, general and administrative901.0K904.0K1.16M765.0K564.0K635.0K
Operating income-3.69M-2.12M-3.56M-5.07M-3.19M-3.20M-3.15M-3.12M-3.03M-3.64M
Depreciation and amortization16.0K69.0K11.0K13.0K16.0K18.0K21.0K21.0K21.0K17.0K
EBITDA-3.67M-2.06M-3.55M-5.06M-3.17M-3.19M-3.13M-3.10M-3.01M-3.63M
Interest expense3.00K
Income before tax-3.57M-2.08M-3.57M-5.01M-3.17M-3.21M-3.17M-3.12M-3.03M-3.64M
Income tax-37.0K144.0K-429.0K-963.0K-439.0K-539.0K-451.0K-496.0K-443.0K-576.0K
Net income-3.53M-1.94M-3.14M-4.04M-2.73M-2.67M-2.71M-2.62M-2.58M-3.07M
Earnings per share, basic-0.00-0.00-0.01-0.01-0.01-0.02-0.02-0.03-0.03-0.04

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents471.0K2.11M2.00M5.00M4.51M5.59M4.13M2.03M3.63M3.86M
Short-term investments1.07M2.00M4.52M6.00M
Receivables747.0K404.0K497.0K1.02M483.0K652.0K531.0K589.0K463.0K692.0K
Inventory-1.00K
Current assets2.29M5.17M3.03M6.13M9.58M12.3M4.77M2.66M4.13M4.60M
Total assets4.81M7.63M3.06M6.17M9.64M12.4M4.86M2.76M4.26M4.74M
Accounts payable1.68M106.0K330.0K402.0K66.0K408.0K516.0K532.0K102.0K164.0K
Current liabilities1.69M1.66M721.0K833.0K411.0K607.0K653.0K688.0K389.0K514.0K
Total debt11.0K
Total liabilities2.10M1.66M721.0K833.0K411.0K607.0K653.0K688.0K389.0K514.0K
Shareholders' equity2.72M5.97M2.34M5.34M9.23M11.8M4.20M2.08M3.87M4.23M
Shares outstanding2.15B538.3M274.9M274.9M274.9M147.0M131.2M97.3M79.9M74.2M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-2.55M-2.37M-3.00M-4.03M-2.56M-2.93M-2.58M-2.29M-2.34M-3.19M
Capital spending-17.0K00-1.00K-3.00K-5.00K-1.00K0-7.00K-76.0K
Free cash flow-2.56M-2.37M-3.00M-4.03M-2.56M-2.93M-2.58M-2.29M-2.35M-3.27M
Cash from investing916.0K-2.08M4.52M1.48M-6.00M-1.00K-7.00K1.93M
Cash from financing-7.00K4.55M10.4M4.67M694.0K2.12M
Change in cash-1.64M105.0K-3.00M490.0K-1.08M1.46M2.10M-1.59M-233.0K-1.26M

Open Financials

Cap table

Built by 6ix from TheraCryf PLC’s releases · as of Aug 20, 2026

Common shares
2,148,963,739
Fully diluted
2,148,963,739

Fully diluted

LineShares
Common shares2,148,963,739

Share count over time

CountShares
Nov 22, 20262,148,963,739

Open Cap table

Shareholders

StakeStakeSharesDateFiling
First Equity Limited12.00%328MOct 12, 2026TR-1 holding notification (FCA)

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alan BargeNon-Executive Director · Since at least May 1, 2025
Alastair SmithChief Executive Officer · Since at least Sep 28, 2026
Andy ThackerNorthstar Communications Investor Relations · Since at least Oct 9, 2026
Edward WardleNon-executive Director · Since at least Sep 28, 2026
Glen ClackChief Medical Officer · Since at least Aug 20, 2026
Guy McDougallNorthstar Communications Investor Relations · Since at least Oct 22, 2026
Helen KuhlmanChief Operating Officer · Since at least Oct 22, 2026
Huw JonesChief Executive Officer · Since at least Oct 22, 2026
Toni HaenninenChief Financial Officer · Since at least Sep 28, 2026

Open People

Log in to ask 6ix AI your own questions about TheraCryf PLC.